GlaxoSmithKline to pass $10B in 2024 vaccine sales, with Merck, Sanofi and Pfizer rounding out the top 4: report

Shingrix may not make it on the top 5 best-selling vaccines list in 2024, but a diversified portfolio will still secure GlaxoSmithKline the lead position in the vaccine industry at that time, followed by Merck &Co., Sanofi, Pfizer and a dark horse biotech, life science commercial intelligence firm Evaluate predicts.